SCHEMBL10189786

SCHEMBL10189786

COc1ccc(-c2nn[nH]c2-c2cc(OC)c(OC)c(OC)c2)cc1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
MEN1 O00255 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KCNH2 Q12809 1/20 0.44
TUBB4A P04350 2/20 0.41
TUBB P07437 2/20 0.41
TUBA3C P0DPH7 2/20 0.41
TUBA1B P68363 2/20 0.41
TUBA4A P68366 2/20 0.41
TUBB4B P68371 2/20 0.41
TUBB3 Q13509 2/20 0.41
TUBB2A Q13885 2/20 0.41
TUBB8 Q3ZCM7 2/20 0.41
TUBA3E Q6PEY2 2/20 0.41
TUBA1A Q71U36 2/20 0.41
TUBA1C Q9BQE3 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3297652 0.84 TUBB4A (0.55) KDM4EALDH1A1HPGDMEN1MAPK1
Hydrochloric Acid SCHEMBL407331 0.83 TUBB4A (0.54) KDM4EALDH1A1HPGDMEN1MAPK1
SCHEMBL31237897 0.82 TUBB4A (0.52) KDM4EALDH1A1HPGDMEN1MAPK1
SCHEMBL407740 0.82 KDM4E (0.45) KDM4EALDH1A1HPGDMEN1MAPK1
SCHEMBL412017 0.82 FYN (0.51) KDM4EALDH1A1HPGDMEN1MAPK1
SCHEMBL408776 0.81 ACHE (0.46) KDM4EALDH1A1HPGDMEN1MAPK1
SCHEMBL10189742 0.81 CCNB2 (0.38) ALDH1A1MEN1KMT2AKCNH2
SCHEMBL14401669 0.81 KDM4E (0.42) KDM4EALDH1A1HPGDMEN1MAPK1
SCHEMBL411698 0.80 TUBB4A (0.56) KDM4EALDH1A1HPGDMEN1MAPK1
SCHEMBL411640 0.80 KDM4E (0.44) KDM4EALDH1A1HPGDMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 KDM4E 2492/4885ALDH1A1 1872/4885HPGD 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.